| Drug General Information |
| Drug ID |
D01SJS
|
| Former ID |
DIB016805
|
| Drug Name |
AXL-1717
|
| Synonyms |
BVT-51004; IGF-1 inhibitors, Axelar/Biovitrum; IGF-1 inhibitors, Karolinska/Biovitrum; Insulin-like growth factor 1 inhibitors, Axelar/Biovitrum
|
| Drug Type |
Small molecular drug
|
| Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Phase 2 |
[1],
[2]
|
|---|
| Company |
Axelar AB
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C22H22O8
|
| InChI |
InChI=1S/C22H22O8/c1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h4-7,13,18-20,23H,8-9H2,1-3H3/t13-,18+,19+,20-/m0/s1
|
| InChIKey |
YJGVMLPVUAXIQN-HAEOHBJNSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
93086, 602433, 8138202, 8195191, 11364530, 11367092, 11369654, 11372800, 11375671, 11377816, 11484215, 11488336, 11491486, 11493650, 11495450, 11537779, 14831259, 14929033, 26612705, 26680654, 26758962, 29216394, 43128600, 47423461, 48317613, 48410508, 49971903, 50110901, 53787335, 57318718, 71831592, 78208362, 85787406, 91010625, 92124958, 92718093, 103192207, 104352939, 124637742, 126628593, 135148884, 142572795, 152104948, 162198638, 162248061, 163620930, 163686251, 163687885, 163835502, 174006597
|
| Target and Pathway |
| Target(s) |
Insulin-like growth factor I receptor |
Target Info |
Inhibitor |
[3]
|
|---|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
HIF-1 signaling pathway
|
|
FoxO signaling pathway
|
|
Oocyte meiosis
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
AMPK signaling pathway
|
|
Focal adhesion
|
|
Adherens junction
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Long-term depression
|
|
Ovarian steroidogenesis
|
|
Progesterone-mediated oocyte maturation
|
|
Pathways in cancer
|
|
Transcriptional misregulation in cancer
|
|
Proteoglycans in cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Melanoma
|
|
PANTHER Pathway
|
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade
|
|
Insulin/IGF pathway-protein kinase B signaling cascade
|
|
Pathway Interaction Database
|
Plasma membrane estrogen receptor signaling
|
|
SHP2 signaling
|
|
IGF1 pathway
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
Integrins in angiogenesis
|
|
Stabilization and expansion of the E-cadherin adherens junction
|
|
Reactome
|
IRS-related events triggered by IGF1R
|
|
SHC-related events triggered by IGF1R
|
|
WikiPathways
|
Senescence and Autophagy in Cancer
|
|
Insulin Signaling
|
|
Endochondral Ossification
|
|
Focal Adhesion
|
|
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
|
|
Apoptosis
|
|
Signaling Pathways in Glioblastoma
|
|
TSH signaling pathway
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
| References |
| REF 1 | ClinicalTrials.gov (NCT01561456) Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung. U.S. National Institutes of Health. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7873). |
|---|
| REF 3 | Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol. 2011 Apr;50(3):441-7. |
|---|
